APDN Form 8k
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): March 22,
2006
Applied
DNA Sciences, Inc
(Exact
Name of Registrant as Specified in Charter)
|
Nevada
(State
or Other Jurisdiction
of
Incorporation)
|
002-90539
(Commission
File Number)
|
59-2262718
(IRS
Employer
Identification
No.)
|
25
Health Sciences Drive, Suite 113
Stony
Brook, New York 11790
(Address
of Principal Executive Offices) (Zip Code)
631-444-6862
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2 below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d- 2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e- 4(c))
Item
5.02 Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers.
(b)
Departure of Directors.
On
March
22, 2006, Peter Brocklesby notified Applied DNA Sciences, Inc. (the “Company”)
that he was resigning his positions as President of the Company and APDN
(B.V.I.) Inc., its wholly-owned subsidiary, and as a member of the Board of
Directors, effective as of such date. The resignation was not a result of any
disagreement with the Company on any matter relating to the Company’s
operations, policies or practices. The Company appreciates Mr. Brocklesby’s
service as President of the Company and its subsidiary and as a member of its
Board of Directors.
Also
on
March 22, 2006, Lawrence Lee notified the Company that he was resigning his
positions as Chief Technology Strategist and a member of the Board of Directors
of the Company, effective as of such date. The resignation was not a result
of
any disagreement with the Company on any matter relating to the Company’s
operations, policies or practices. The Company appreciates Mr. Lee’s service as
Chief Technology Strategist of the Company and as a member of its Board of
Directors.
Item
8.01 Other
Events.
On
March
23, 2006, the Company issued a press release announcing the resignations
described under Item 5.02 above and the appointments of Mr. Hayward and Mr.
Simon to the Board of Directors on March 17, 2006. A copy of the press release
is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
Exhibit
99.1 Press
release of Applied DNA Sciences, Inc., dated March 23, 2006
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
Applied
DNA Sciences, Inc. |
| |
(Registrant) |
|
|
|
| Date: March
23, 2006 |
By: |
/s/ James
Hayward |
| |
James
Hayward |
| |
Chief
Executive Officer |
| Exhibit No. |
|
Description of
Exhibit |
| |
|
|
| 99.1 |
|
Press
Release of Applied DNA Sciences, Inc., dated March 23, 2006. |
| |
|
|